Breast Cancer and Tamoxifen Resistance
Author Information
Author(s): Zhou Yamei, Yau Christina, Gray Joe W, Chew Karen, Dairkee Shanaz H, Moore Dan H, Eppenberger Urs, Eppenberger-Castori Serenella, Benz Christopher C
Primary Institution: Buck Institute for Age Research
Hypothesis
Increased NFκB and AP-1 transcriptional activity is associated with antiestrogen resistant breast cancer.
Conclusion
Increased NFκB and AP-1 transcriptional responses are linked to tamoxifen resistant breast cancer and early metastatic relapse, particularly in younger patients.
Supporting Evidence
- High expression of NFκB and AP-1 upregulated genes was associated with early metastatic relapse.
- Three genes (cyclin D1, uPA, and VEGF) were identified as significant predictors of relapse-free survival.
- Younger patients experienced more frequent and earlier relapses despite similar treatment.
Takeaway
Some breast cancers don't respond to tamoxifen because they have higher activity of certain proteins that help them grow. Finding ways to block these proteins might help the treatment work better.
Methodology
The study used two tamoxifen-resistant breast cancer cell lines and expression microarray data from 54 breast cancer cases to analyze gene expression related to NFκB and AP-1 activity.
Potential Biases
Potential biases may arise from the selection of cases and the retrospective nature of the analysis.
Limitations
The study is exploratory and based on a limited number of cases, which may not represent all breast cancer patients.
Participant Demographics
The study included node-negative ER-positive breast cancer cases, with a focus on younger patients (≤ 45 years) and older patients (≥ 70 years).
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website